Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04591262 | A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants | PHASE1 | COMPLETED | 6 | — | — | Nov 10, 2020 | Jan 28, 2021 | Feb 21, 2021 | 2 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| PF-06826647 600 mg PO>PF-06826647 600 mg PO+100 ug IV | EXPERIMENTAL | PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2. |
| Name | Type | Description |
|---|---|---|
| 14C-PF-06826647-LR 600 mg PO | DRUG | 14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep |
| PF-06826647 600 mg PO | DRUG | Unlabeled PF-06826647 600 mg |
| 14C-PF-06826647 100 ug IV | DRUG | 14C-PF-06826647 100 ug IV |
Inclusion Criteria: * Healthy Male participants must be 18 to 55 years of age, inclusive. * Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, including BP and pulse rate measurement, laboratory tests, and 12 lead ECG. * Pa...